Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 97Lung Neoplasms 35Colorectal Neoplasms 35Pancreatic Neoplasms 13Adenocarcinoma of Lung 10Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Colonic Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Breast Neoplasms 6Rectal Neoplasms 5Melanoma 5Endometrial Neoplasms 5Stomach Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Triple Negative Breast Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Pleural Effusion, Malignant 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Pancreatic Ductal 2

Interventions

Panitumumab 1PLX8394 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Cetuximab × Thoracic × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡